21 unchanged sentences
Our responsibility is to express an opinion on the Company’s internal control over financial reporting based on our audit.
−Removed: We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S.
+Added: We are a public accounting firm registered with the PCAOB and are required to be
+Added: independent with respect to the Company in accordance with the U.S.
federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.
14 unchanged sentences
Changes in Internal Controls Over Financial Reporting
−Removed: There were no changes in our internal control over financial reporting during the quarter ended December 31, 2019 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
+Added: Management has completed the evaluation and integration of the internal controls of the acquired Progenics business into the Company’s existing operations for the year ended December 31, 2020.
+Added: After such evaluation and integration, there were no material changes in the Company’s internal control over financial reporting during the quarter ended December 31, 2020, that have materially affected, or are reasonably likely to materially affect, the Company’s internal control over financial reporting.
+Added: As a result of the COVID-19 pandemic, certain employees began working remotely in March 2020.
+Added: Notwithstanding these changes to the working environment, we have not identified any material changes in our internal control over financial reporting from the commencement of such changes.
+Added: We are continually monitoring and assessing the pandemic status to determine any potential impact on the design and operating effectiveness of our internal controls over financial reporting.
Other Information
30 unchanged sentences
Incorporated by Reference
−Removed: Description of Exhibits
+Added: Number Description of Exhibits Form File Number Exhibit Filing Date
2.1 Agreement and Plan of Merger, dated as of October 1, 2019, among Lantheus Holdings, Inc., Plato Merger Sub, Inc.
and Progenics Pharmaceuticals, Inc.
−Removed: October 2, 2019
+Added: 8-K 001-36569 10.1 October 2, 2019
3.1 Amended and Restated Certificate of Incorporation of Lantheus Holdings, Inc.
−Removed: April 27, 2018
+Added: 8-K 001-36569 3.1 April 27, 2018
3.2 Amended and Restated Bylaws of Lantheus Holdings, Inc.
−Removed: April 27, 2018
+Added: 8-K 001-36569 3.2 April 27, 2018
4.1 Common Stock Certificate.
−Removed: June 30, 2015
+Added: 8-K 001-36569 4.1 June 30, 2015
4.2* Description of Registrant’s Securities
−Removed: Sales Agreement, dated as of April 1, 2009, between Lantheus Medical Imaging, Inc.
−Removed: and NTP Radioisotopes (Pty) Ltd.
−Removed: December 23, 2010
−Removed: Amendment No.
−Removed: 1 to Sales Agreement, dated as of January 1, 2010, between Lantheus Medical Imaging, Inc.
−Removed: and NTP Radioisotopes (Pty) Ltd.
−Removed: December 1, 2010
−Removed: Amendment No.
−Removed: 2 to Sales Agreement, dated as of January 1, 2010, between Lantheus Medical Imaging, Inc.
−Removed: and NTP Radioisotopes (Pty) Ltd.
10.4+ Lantheus Holdings, Inc.
2008 Equity Incentive Plan.
−Removed: October 6, 2010
+Added: S-4 333-169785 10.18 October 6, 2010
10.5+ Amendment No.
1 unchanged sentence
2008 Equity Incentive Plan.
−Removed: October 6, 2010
+Added: S-4 333-169785 10.19 October 6, 2010
10.6+ Amendment No.
1 unchanged sentence
2008 Equity Incentive Plan.
−Removed: October 6, 2010
+Added: S-4 333-169785 10.20 October 6, 2010
10.7+ Form of Option Grant Award Agreement.
−Removed: October 6, 2010
+Added: S-4 333-169785 10.21 October 6, 2010
10.9† Manufacturing and Supply Agreement, dated as of February 1, 2012, for the manufacture of DEFINITY® by and between Lantheus Medical Imaging, Inc.
and Jubilant HollisterStier LLC.
+Added: 10-Q 333-169785 10.2 May 15, 2012
10.10† First Amendment to Manufacturing and Supply Agreement, dated as of May 3, 2012, for the manufacture of DEFINITY® by and between Lantheus Medical Imaging, Inc.
and Jubilant HollisterStier LLC.
−Removed: August 14, 2012
−Removed: Amendment No.
−Removed: 3, effective as of October 1, 2012, to Sales Agreement between Lantheus Medical Imaging, Inc.
−Removed: and NTP Radioisotopes (Pty) Ltd.
+Added: 10-Q 333-169785 10.1 August 14, 2012
10.12+ Lantheus Holdings, Inc.
2013 Equity Incentive Plan.
+Added: 8-K 333-169785 10.1 May 6, 2013
10.13+ Form of Employee Option Grant Award Agreement.
+Added: 8-K 333-169785 10.2 May 6, 2013
10.14+ Form of Non-Employee Director Option Grant Award Agreement.
+Added: 8-K 333-169785 10.3 May 6, 2013
10.15+ 2015 Equity Incentive Plan of Lantheus Holdings, Inc.
−Removed: June 24, 2015
−Removed: Incorporated by Reference
−Removed: Description of Exhibits
+Added: S-1 333-196998 10.37 June 24, 2015
10.16+ Form of 2015 Restricted Stock Agreement of Lantheus Holdings, Inc.
−Removed: June 24, 2015
+Added: S-1 333-196998 10.38 June 24, 2015
10.17+ Form of 2015 Option Award Agreement of Lantheus Holdings, Inc.
−Removed: June 24, 2015
+Added: S-1 333-196998 10.39 June 24, 2015
10.18+ Form of Amendment to the Lantheus Holdings, Inc.
2013 Equity Incentive Plan.
−Removed: June 24, 2015
+Added: S-1 333-196998 10.40 June 24, 2015
10.19+ Form of Amendment to the Lantheus Holdings, Inc.
2008 Equity Incentive Plan.
−Removed: June 24, 2015
+Added: S-1 333-196998 10.41 June 24, 2015
10.20+ Amendment to Lantheus Holdings, Inc.
2015 Equity Incentive Plan.
−Removed: April 28, 2016
+Added: 8-K 001-36569 10.1 April 28, 2016
10.21† Second Amendment, effective September 2, 2016, to the Manufacturing and Supply Agreement, dated as of February 1, 2012 and amended on May 3, 2012, by and between Lantheus Medical Imaging, Inc.
and Jubilant HollisterStier LLC.
−Removed: November 1, 2016
+Added: 10-Q 001-36569 10.2 November 1, 2016
+Added: Incorporated by Reference
+Added: Number Description of Exhibits Form File Number Exhibit Filing Date
10.22+ Second Amendment to Lantheus Holdings, Inc.
2015 Equity Incentive Plan
−Removed: April 28, 2017
+Added: 8-K 001-36569 10.1 April 28, 2017
10.23+ Lantheus Holdings, Inc.
2017 Employee Stock Purchase Plan
−Removed: April 28, 2017
+Added: 8-K 001-36569 10.2 April 28, 2017
10.24† Collaboration and License Agreement by and between Lantheus Medical Imaging, Inc.
and GE Healthcare Limited dated April 25, 2017.
−Removed: August 1, 2017
−Removed: Amendment No.
−Removed: 4 to Sales Agreement, dated as of December 29, 2017, by and between Lantheus Medical Imaging, Inc.
−Removed: and NTP Radioisotopes (SOC) Ltd.
−Removed: February 7, 2018
+Added: 10-Q 001-36569 10.1 August 1, 2017
10.25+ Second Amended and Restated Employment Agreement, effective January 25, 2019, by and between Lantheus Medical Imaging, Inc.
and Mary Anne Heino.
−Removed: February 20, 2019
+Added: 10-K 001-36569 10.68 February 20, 2019
10.26+ Employment Agreement dated as of November 22, 2013, by and between Lantheus Medical Imaging, Inc.
and Michael Duffy.
−Removed: February 20, 2019
+Added: 10-K 001-36569 10.69 February 20, 2019
10.27+ Form of Severance Agreement (executives with existing employment agreements).
−Removed: February 20, 2019
+Added: 10-K 001-36569 10.70 February 20, 2019
10.28+ Form of Severance Agreement (executives without existing employment agreements).
−Removed: February 20, 2019
+Added: 10-K 001-36569 10.71 February 20, 2019
10.29+ Third Amendment to Lantheus Holdings, Inc.
2015 Equity Incentive Plan
−Removed: April 30, 2019
−Removed: Retirement Agreement, effective April 18, 2019, between Lantheus Medical Imaging, Inc.
−Removed: and Cesare Orlandi, M.D.
−Removed: July 25, 2019
+Added: 10-Q 001-36569 10.1 April 30, 2019
10.30+ Fourth Amendment to Lantheus Holdings, Inc.
2015 Equity Incentive Plan
−Removed: July 25, 2019
+Added: 10-Q 001-36569 10.2 July 25, 2019
10.31 Credit Agreement dated as of June 27, 2019 by and among Wells Fargo Bank, N.A., as administrative agent and collateral agent, each of the lenders from time to time party thereto, Lantheus Medical Imaging, Inc., as borrower, and Lantheus Holdings, Inc.
−Removed: July 25, 2019
−Removed: Volume and Pricing Amendment, dated as of October 31, 2019, by and between Lantheus Medical Imaging, Inc.
−Removed: and NTP Radioisotopes (SOC) Ltd.
+Added: 10-Q 001-36569 10.3 July 25, 2019
+Added: 10.32 Amendment No.
+Added: 1 to Credit Agreement, dated as of June 19, 2020, among Lantheus Medical Imaging, Inc., as borrower, Lantheus Holdings, Inc.
+Added: and Wells Fargo Bank, N.A., as administrative agent and collateral agent*
+Added: 10-Q 001-36539 10.2 July 31, 2020
+Added: 10.33 Contingent Value Rights Agreement dated as of June 19, 2020, by and between Lantheus Holdings, Inc.
+Added: and Computershare Trust Company, N.A., as rights agent.
+Added: 8-K 001-36569 10.1 June 22, 2020
+Added: 10.34 Lantheus Holdings, Inc.
+Added: 2005 Stock Incentive Plan (f/k/a Progenics Pharmaceuticals, Inc.
+Added: 2005 Stock Incentive Plan).
+Added: S-8 333-239491 4.4 June 26, 2020
+Added: 10.35 Lantheus Holdings, Inc.
+Added: 2018 Performance Incentive Plan (f/k/a Progenics Pharmaceuticals, Inc.
+Added: 2018 Performance Incentive Plan).
+Added: S-8 333-239491 4.5 June 26, 2020
+Added: 10.36 License Agreement, dated February 3, 2011, by and between Salix Pharmaceuticals, Inc., the Registrant, Progenics Pharmaceuticals Nevada, Inc.
+Added: and Excelsior Life Sciences Ireland Limited.
+Added: 10-Q 000-23143 10.37(16) May 10, 2011
+Added: 10.37 Lease, dated December 31, 2015, between the Registrant and WTC TOWER 1 LLC.
+Added: 8-K 000-23143 10.46 (21) January 5, 2016
+Added: 10.38 Loan Agreement, dated November 4, 2016, between the Registrant through its wholly-owned subsidiary MNTX Royalties Sub LLC and Healthcare Royalty Partners III, L.P.
+Added: 8-K 000-23143 10.53(24) November 7, 2016
21.1* Subsidiaries of Lantheus Holdings, Inc.
5 unchanged sentences
Section 1350.
−Removed: XBRL Instance Document
−Removed: XBRL Taxonomy Extension Schema
−Removed: XBRL Taxonomy Extension Calculation
−Removed: XBRL Taxonomy Extension Definition
−Removed: XBRL Taxonomy Extension Labels
−Removed: XBRL Taxonomy Extension Presentation
+Added: 101.INS* Inline XBRL Instance Document
+Added: 101.SCH* Inline XBRL Taxonomy Extension Schema Document
+Added: 101.CAL* Inline XBRL Taxonomy Extension Calculation Linkbase Document
+Added: 101.DEF* Inline XBRL Taxonomy Extension Definition Linkbase Document
+Added: 101.LAB* Inline XBRL Taxonomy Extension Labels Linkbase Document
+Added: 101.PRE* Inline XBRL Taxonomy Extension Presentation Linkbase Document
+Added: 104* Cover Page Interactive Data File (embedded within the Inline XBRL document)
________________________________
16 unchanged sentences
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.
−Removed: /S/ MARY ANNE HEINO
−Removed: Chief Executive Officer, President and Director
−Removed: (Principal Executive Officer)
−Removed: February 25, 2020
+Added: Signature Title Date
+Added: /S/ MARY ANNE HEINO Chief Executive Officer, President and Director
+Added: (Principal Executive Officer) February 25, 2021
Mary Anne Heino
2 unchanged sentences
Chief Financial Officer and Treasurer
−Removed: (Principal Financial and Accounting Officer)
−Removed: February 25, 2020
+Added: (Principal Financial and Accounting Officer) February 25, 2021
Marshall, Jr.
−Removed: /S/ BRIAN MARKISON
−Removed: Chairman of the Board of Directors
−Removed: February 25, 2020
+Added: /S/ BRIAN MARKISON Chairman of the Board of Directors February 25, 2021
Brian Markison
−Removed: February 25, 2020
/S/ SAMUEL R.
−Removed: February 25, 2020
−Removed: February 25, 2020
−Removed: February 25, 2020
−Removed: /S/ KENNETH J.
−Removed: February 25, 2020
−Removed: February 25, 2020
−Removed: February 25, 2020
−Removed: February 25, 2020
+Added: LENO Director February 25, 2021
+Added: MCHUGH Director February 25, 2021
+Added: PRUDEN Director February 25, 2021
+Added: /S/ GERARD BER Director February 25, 2021
+Added: ROBERTSON Director February 25, 2021
+Added: /S/ HEINZ MAUSLI Director February 25, 2021
+Added: THRALL Director February 25, 2021
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.